“This biomarker is linked with the strength of a patient’s immune system,” says Dr. Malek. http://divineurl.com/medicalinterview17138“Based on these new findings, we may be able to predict who will respond better and tailor immunologic therapies for patients for optimum response.” Dr. Caimi’s team also had two other related posters which used the same patient cohort to further determine risk stratification in DBCL patients. In Abstract #3611, they showed that patients who experienced venous thrombotic events after diagnosis had poorer outcomes and also validated a method to identify patients at risk of venous thromboembolic events (VTEs). In Abstract #1863, the researchers found that DBCL patients older than 75 have a higher mortality risk following diagnosis. These patients respond equally well to treatment but have additional risk for complications such as heart attacks and blood clots. “These studies in total provide us with important new information on how to modify treatments for certain patients,” says Dr. Caimi, who is also Assistant Professor at the School of Medicine.
For the original version including any supplementary images or video, visit https://www.eurekalert.org/pub_releases/2016-12/uhcm-aim120216.php